Why the study?
Does culprit-lesion-only PCI reduce the risk of death or renal-replacement therapy compared to immediate multivessel PCI in patients with acute myocardial infarction and cardiogenic shock?
Does culprit-lesion-only PCI reduce the risk of death or renal-replacement therapy compared to immediate multivessel PCI in patients with acute myocardial infarction and cardiogenic shock?
In patients with AMI and cardiogenic shock, culprit-lesion-only PCI reduces the 30-day risk of death or renal replacement therapy compared to immediate multivessel PCI, though 1-year mortality does not differ significantly.
Answers are grounded in this paper and cite their sources.
Supports culprit-lesion-only PCI in AMI with cardiogenic shock; challenges prior consensus favoring multivessel PCI.
Among patients with acute myocardial infarction and cardiogenic shock, the risk of death or renal-replacement therapy at 30 days was lower with culprit-lesion-only PCI than with immediate multivessel PCI, and mortality did not differ significantly between the two groups at 1 year of follow-up. (Funded by the European Union Seventh Framework Program and others; CULPRIT-SHOCK ClinicalTrials.gov number, NCT01927549 .).
No takes yet. Share an insight, caveat, or question.
Thiele et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: